Form D · Biotechnology
Sentien Biotechnologies, Inc.
Medford, MA · CIK 0001650699
Offering snapshot reported Aug 12, 2015 · SEC filing
- Reported sold
- $1.05M Offering amount: $1.2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 5, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 12, 2015 | Initial | $1,049,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-245621
Source: Form D, filed Aug 12, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Greg Bailey | Director |
| Rich Ganz | Director |
| Martin Heidecker | Director |
| Brian Miller | Director, Executive |
| Biju Parekkadan | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
196 Boston Avenue Suite 2200
Medford, MA, 02155
Medford, MA, 02155